Size-fractionated heparins have differential effects on human neutrophil function in vitro

British Journal of Pharmacology

Volumn 151, Issue 6, 2007, Pages 837-843

  Lever, R ^a   Lo, W T ^b   Faraidoun, M ^a   Amin, V ^a   Brown, R A ^b   Gallagher, J ^c   Page, C P ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Elastase; Endothelium; Heparin; Inflammation; Neutrophil

Indexed keywords

CARBOHYDRATE; ELASTASE; FORMYLMETHIONYLLEUCYLPHENYLALANINE; INTERLEUKIN 1BETA; LOW MOLECULAR WEIGHT HEPARIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; FRACTIONATION; HUMAN; IN VITRO STUDY; MOLECULAR SIZE; MOLECULAR WEIGHT; NEUTROPHIL; NORMAL HUMAN; PRIORITY JOURNAL;

ANTICOAGULANTS; CELL ADHESION; CHEMICAL FRACTIONATION; ENDOTHELIUM, VASCULAR; HEPARIN; HUMANS; INTERLEUKIN-1BETA; MOLECULAR WEIGHT; N-FORMYLMETHIONINE LEUCYL-PHENYLALANINE; NEUTROPHILS; PANCREATIC ELASTASE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 34447572776     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707298     Document Type: Article

References (44)

1. Albaugh G, Kann B, Strande L, Vemulapalli P, Hewitt C, Alexander JB (2001). Nicotine induces endothelial TNF-α expression, which mediates growth retardation in vitro. J Surg Res 99: 381-384.
2. Bazzoni G, Nuñez AB, Mascellani G, Bianchini P, Dejana E, Del Maschio A (1992). Effect of heparin, dermatan sulfate, and related oligo-derivatives on human polymorphonuclear leukocyte functions. J Lab Clin Med 121: 268-275.
3. Brown RA, Allegra L, Matera MG, Page CP, Cazzola M (2006). Additional clinical benefit of enoxaparin in COPD patients receiving salmeterol and fluticasone propionate in combination. Pulm Pharmacol Ther 19: 419-424.
4. Brown RA, Lever R, Jones NA, Page CP (2003). Effects of heparin and related molecules upon neutrophil aggregation and elastase release in vitro. Br J Pharmacol 139: 845-853.
5. Cai TQ, Wright SD (1996). Human leukocyte elastase is an endogenous ligand for the integrin CR3 (CD11b/CD18, Mac-1, alpha M beta 2) and modulates polymorphonuclear leukocyte adhesion. J Exp Med 184: 1213-1223.
6. Champagne B, Tremblay P, Cantin A, St. Pierre Y (1998). Proteolytic cleavage of ICAM-1 by human neutrophil elastase. J Immunol 161: 6398-6405.
7. Diamond MS, Alon R, Parkos CA, Quinn MT, Springer TA (1995). Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD18). J Cell Biol 130: 1473-1482.
8. Doring G (1994). The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 150: S114-S117.
9. Gallagher JT (1998). The interaction and regulation of basic and acidic fibroblast growth factors by heparan sulphate. Trends Glycosci Glycotechnol 10: 137-144.
10. Goger B, Halden Y, Rek A, Mosl R, Pye D, Gallagher J et al. (2002). Different affinities of glycosaminoglycan oligosaccharides for monomeric and dimeric interleukin-8: a model for chemokine regulation at inflammatory sites. Biochemistry 41: 1640-1646.
11. Jaques LB (1979). Heparins - anionic polyelectrolyte drugs. Pharmacol Rev 31: 99-167.
12. Jones NA, Boswell-Smith V, Lever R, Page CP. (2005). The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther 18: 93-101.
13. Lafuma C, Frisdal E, Harf A, Robert L, Hornebeck W (1991). Prevention of leucocyte elastase-induced emphysema in mice by heparin fragments. Eur Respir J 8: 1004-1009.
14. Laghi-Pasini F, Pasqui AL, Ceccatelli L, Di Perri T (1983). Heparin inhibits FMLP and Con-A dependent activation of human polymorphonuclear leucocytes in vitro. Int J Tissue React 5: 145-151.
15. Lever R, Hoult JRS, Page CP (2000). The effects of heparin and related molecules upon the adhesion of polymorphonuclear leucocytes to vascular endothelium in vitro. Br J Pharmacol 129: 533-540.
16. Lever R, Page CP (2002). Novel drug development opportunities for heparin. Nat Rev Drug Discov 1: 140-148.
17. Ley K, Cerrito M, Arfors K-E (1991). Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am J Physiol 260: H1667-H1673.
18. Lyon M, Rushton G, Askari JA, Humphries MJ, Gallagher JT (2000). Elucidation of the structural features of heparan sulfate important for interaction with the Hep-2 domain of fibronectin. J Biol Chem 275: 4599-4606.
19. Lyon M, Rushton G, Gallagher JT (1997). The interaction of the transforming growth factor-βs with heparin/heparan sulphate is isoform specific. J Biol Chem 272: 18000-18006.
20. Maccarana M, Lindahl U (1993). Mode of interaction between platelet factor 4 and heparin. Glycobiology 3: 271-277.
21. Mayo JW, Carlson DM (1970). Effect of alkali and sodium borohydride at alkaline pH on N-acetylchondrosine: reduction versus cleavage. Carbohydr Res 15: 300-303.
22. Oudijk EJ, Nijhuis EH, Zwank MD, van de Graaf EA, Mager HJ, Coffer PJ et al. (2005). Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax 60: 538-544.
23. Pellegrini L (2001). Role of heparan sulphate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 11: 629-634.
24. Petitou M, Herault J-P, Bernat A, Driguez P-A, Duchaussoy P, Lormeau J-C et al. (1999). Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398: 417-422.
25. Ranta V, Orpana A, Carpen O, Turpeinen U, Ylikorkala O, Viinikka L (1999). Human vascular endothelial cells produce tumor necrosis factor-alpha in response to proinflammatory cytokine stimulation. Crit Care Med 27: 2184-2187.
26. Rao NV, Kennedy TP, Rao G, Ky N, Hoidal JR (1990). Sulfated polysaccharides prevent human leukocyte elastase-induced acute lung injury and emphysema in hamsters. Am Rev Respir Dis 2: 407-412.
27. Salas A, Sans M, Soriano A, Reverter JC, Anderson DC, Pique JM et al. (2000). Heparin attenuates TNF-alpha induced inflammatory response through a CD11b dependent mechanism. Gut 47: 88-96.
28. Sasaki M, Herd CM, Page CP (1993). Effect of heparin and a low-molecular weight heparinoid on PAF-induced airway responses in neonatally immunized rabbits. Br J Pharmacol 110: 107-112.
29. Seeds EAM, Horne AP, Tyrrell DJ, Page CP (1995). The effect of inhaled heparin and related glycosaminoglycans on allergen-induced eosinophil infiltration in guinea-pigs. Pulm Pharmacol 8: 97-105.
30. Seeds EAM, Page CP (2001). Heparin inhibits allergen-induced eosinophil infiltration into guinea-pig lung via a mechanism unrelated to its anticoagulant activity. Pulm Pharmacol Ther 14: 111-119.
31. Silvestro L, Viano I, Macario M, Colangelo D, Montrucchio G, Panico S et al. (1994). Effects of heparin and its desulfated derivatives on leukocyte-endothelial adhesion. Sem Thromb Haemost 20: 254-258.
32. Smailbegovic A, Lever R, Page CP (2001). The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. Br J Pharmacol 134: 827-836.
33. Stringer SE, Gallagher JT (1997). Specific binding of the chemokine platelet factor 4 to heparan sulphate. J Biol Chem 272: 20508-20514.
34. Stringer SE, Kandola BS, Pye DA, Gallagher JT (2003). Heparin sequencing. Glycobiology 13: 97-107.
35. Tangelder GJ, Arfors K-E (1991). Inhibition of leukocyte rolling in venules by protamine and sulfated polysaccharides. Blood 7: 1565-1571.
36. Teixeira MM, Hellewell PG (1993). Suppression by intradermal administration of heparin of eosinophil accumulation but not oedema formation in inflammatory reactions in guinea-pig skin. Br J Pharmacol 110: 1496-1500.
37. Turnbull JE, Fernig DE, Ke Y, Wilkinson MC, Gallagher JT (1992). Identification of the basic fibroblast growth factor binding sequence in fibroblast heparan sulphate. J Biol Chem 267: 10337-10341.
38. Tyrrell DJ, Horne AP, Holme KR, Preuss JM, Page CP (1999). Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 46: 151-208.
39. Vancheri C, Mastruzzo C, Armato F, Tomaselli V, Magri S, Pistorio MP et al. (2001). Intranasal heparin reduces eosinophil recruitment after nasal allergen challenge in patients with allergic rhinitis. J Allergy Clin Immunol 108: 703-708.
40. Walker A, Gallagher JT (1996). Stuctural domains of heparan sulphate for specific recognition of the C-terminal heparin-binding domain of human plasma fibronectin (HepII). Biochem J 317: 871-877.
41. Walker A, Turnbull JE, Gallagher JT (1994). Specific heparan sulphate saccharides mediate the activity of basic fibroblast growth factor. J Biol Chem 269: 931-935.
42. Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA (1996). The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin and heparanases. J Biol Chem 271: 10079-10086.
43. Xie X, Thorlacius H, Raud J, Hedqvist P, Lindbom L (1997). Inhibitory effect of locally administered heparin on leukocyte rolling and chemoattractant-induced firm adhesion in rat mesenteric venules in vivo. Br J Pharmacol 122: 906-910.
44. Yanaka K, Nose T, Hindman BJ (1996). Heparin ameliorates brain injury by inhibiting leukocyte accumulation. Stroke 27: 2146-2147.